How SAFE Notes and Convertible Notes Stack Up and Silently Destroy Your Series B Cap Table

When founders stack SAFEs and convertible notes during the seed stage, they rarely model what happens when every instrument converts at once. The short answer: mixed SAFEs and notes create more dilution than founders expect, because each instrument converts under its own rules, and the combined effect is calculated on a fully diluted basis that includes accrued note interest, option pool assumptions, and every outstanding equity promise. By the time a Series B lead investor opens your cap table, that seed paper is no longer a future problem. It is the first number they model against the round.

This article is part of the Hub 16 series on cap table issues that kill a Series B before the lead investor reads your deck. That parent guide covers the full landscape of structural problems that surface during institutional diligence. This spoke goes deep on one specific problem: what happens when your seed financing mixed SAFEs and convertible notes, and why the combined overhang reshapes Series B economics in ways most founders do not see coming.

The core issue: SAFEs and convertible notes are not interchangeable instruments. They convert differently, price differently, and interact with option pool expansion in different ways. Stack both types together and the dilution compounds in ways that a single instrument type would not. If you want a broader breakdown of how each instrument fits into a capital stack, the capital stack explainer covering equity, debt, and SAFEs is a useful starting point before working through the mechanics below.

Here is what this guide covers:

• How post-money SAFEs, pre-money SAFEs, and convertible notes each convert differently
• What a Series B lead investor models when they see a mixed stack
• A worked example showing how two SAFEs and one note interact before the round closes
• The compounding effects of accrued interest and option pool refresh
• What founders should do before diligence surfaces the problem for them

Why Stacked SAFEs and Notes Are Not the Same Kind of Dilution

Most founders treat SAFEs and convertible notes as functionally equivalent. They are not. Each instrument converts using different pricing logic, and when you hold both types on the same cap table, the differences stop being academic.

The real danger in a mixed stack is not any single instrument. It is that each one converts independently, using its own math, while the lead investor adds them all up on a single fully diluted model. Carta's SAFE and convertible note calculator allows founders to run exactly this scenario before diligence does it for them.

What a Series B Lead Actually Models When Your Seed Paper Catches Up With You

A Series B lead investor does not read your deck first. They open your cap table. Before they engage on valuation or terms, they run a fully diluted model that answers five specific questions:

1. What does the founder own today on a fully diluted basis? Not issued shares. Fully diluted, meaning every SAFE, every note, every option grant, and every pool reserve is included.
2. What will each convertible instrument become in shares at the Series B price? Each SAFE and note is modeled independently at the proposed round valuation, including any accrued interest on notes.
3. How much of the pre-money does the convertible overhang consume? If SAFEs and notes collectively convert into 20% to 25% of the company before the new money lands, the lead investor's ownership target becomes harder to achieve without a price that hurts the founder.
4. Is there room for a meaningful option pool refresh? Most Series B leads require a 10% to 15% post-round pool. That expansion comes out of the pre-money, compounding what the convertibles already took.
5. Does the cap table signal discipline or desperation? A mixed stack with inconsistent caps, varied discount rates, and notes at different maturities raises a question about how the company approached early financing. That question does not disappear after the round closes.

The real risk: a messy mixed stack does not just reduce founder ownership. It reduces the amount of the company the lead investor can buy at a price that makes the deal worth leading. That is when repricing conversations start, or the lead walks.

Worked Example: How a SAFE Stack and a Note Collide Before the Series B Closes

Here is a clean scenario. A founder raised $1.5M in seed capital across three instruments before the Series B.

The note does not convert at $500K. After 24 months at 7% annual interest, the converting balance is approximately $570K. At a $10M cap, that note converts into roughly 5.7% of the company. With the 20% discount applied, if the Series B prices below $12.5M pre-money, the discount triggers instead and the note converts at an even lower effective price.

What the founder modeled: roughly 16% dilution from seed paper ($500K + $500K + $500K against their caps).

That is nearly 25% of the company consumed before the Series B investor writes a check. If the lead wants 20% for their capital, the founder is now below 55% ownership post-round. For a company that started at 100%, that trajectory matters to future round economics and governance.

According to 2026 benchmarks from Carta's market data, total SAFE dilution above 25% to 30% before a priced round is already considered punishing. Add a note with accrued interest and a pool refresh, and most founders land well inside that range without realizing it.

This is exactly the scenario covered in more detail in the companion spoke on how three stacked SAFEs detonate at your Series B.

The Hidden Compounding Problem: Accrued Interest, Option Pool Refresh, and Pricing Pressure

The worked example above shows the math. Here is what makes it worse in practice.

Three factors that compound the overhang

1. Accrued interest grows the note balance silently. Most founders remember the principal. They forget the interest. At the median Q1 2025 convertible note rate of 7%, a $500K note outstanding for 24 months converts with roughly $70K in additional principal. That extra balance buys more shares at the cap price, increasing dilution beyond what the original check amount suggested.

2. Option pool expansion hits the pre-money, not the post-money. Series B leads typically require a refreshed option pool of 10% to 15% as a condition of the term sheet. That expansion is priced into the pre-money valuation, which means founders and existing shareholders absorb it before the new capital lands. In the worked example above, an 8.5% pre-money pool expansion added more dilution than either individual SAFE.

3. Low-cap SAFEs and uncapped notes create a pricing floor problem. When a SAFE was issued at a $5M or $6M cap and the Series B is priced at $40M or $50M pre-money, that early investor is getting a massive discount on their conversion price. That is not a problem for them. It is a problem for the founder and the new lead, because the effective cost of that early capital was far higher than it appeared at the time. The convertible note overhang problem is especially acute when notes carry no cap at all.

Once these three factors stack together, the lead investor's model shows a company where the founder owns less, the new money buys less, and the round economics get tighter before a single negotiation point is even reached.

What Founders Should Do Before a Lead Investor Does It for Them

The overhang is fixable. But it is much easier to fix before a lead investor has already modeled it and drawn conclusions about your financing discipline.

• Build one fully diluted model now. Include every SAFE (noting whether it is pre-money or post-money), every convertible note with accrued interest projected to your expected Series B close date, every outstanding option grant, and the remaining pool balance. Use Carta's SAFE and convertible note calculator as a starting framework.
• Identify the instruments most likely to surprise you. Low-cap SAFEs, uncapped notes, notes with high discount rates, and anything with MFN or side-letter exposure will convert at terms more aggressive than the headline numbers suggest.
• Model the option pool refresh before the term sheet arrives. Know what a 10% and 15% pre-money pool expansion does to founder ownership at three different Series B valuations. If the answer is uncomfortable, that is information you need before the negotiation, not during it.
• Understand the option pool shuffle mechanics before your lead uses them against you. The pre-money pool expansion is not a negotiating detail. It is a structural dilution event.
• Consider a cap table audit before you go to market. IRC Partners' cap table forensics process reverse-engineers your existing equity structure from seed instruments to model exit scenarios and identify hidden dilution before institutional diligence does.

The lead investor will run this model. The only question is whether you have already run it first.

Frequently Asked Questions‍

How much dilution is too much from stacked SAFEs and notes before a Series B?

Any combined convertible overhang above 25% to 30% of fully diluted shares is considered punishing by most Series B investors, according to 2026 benchmarks from Carta market data. Above that threshold, the lead investor's ownership target becomes harder to achieve at a price that works for both sides, and repricing or round restructuring becomes likely.

Does accrued interest on a convertible note really matter at conversion?

Yes. At the median Q1 2025 convertible note interest rate of 7%, a $500K note outstanding for 24 months converts at approximately $570K. That $70K difference buys additional shares at the cap price, increasing dilution beyond what the original principal suggested. Founders who ignore accrued interest consistently underestimate the note's effective size at conversion.

What is the difference between a pre-money SAFE and a post-money SAFE at Series B?

A post-money SAFE locks in a fixed ownership percentage at signing. A $500K SAFE on a $10M post-money cap always converts to exactly 5%, regardless of the Series B valuation. A pre-money SAFE references the pre-money valuation at conversion, so the share count varies with the round price. Post-money SAFEs are more predictable but are fully additive when stacked, meaning three post-money SAFEs at 5%, 4%, and 3% always produce 12% combined dilution with no scenario where a higher valuation reduces that number.

When does a convertible note discount trigger instead of the cap?

The discount applies when the round price is low enough that the discounted price is better for the investor than the cap price. For a note with a $10M cap and a 20% discount, the discount triggers at any priced round below $12.5M pre-money. At a $40M Series B, the cap is almost certainly the binding term and the discount becomes irrelevant.

Can a founder renegotiate SAFE or note terms before a Series B?

Yes, but it requires investor consent and is not always achievable. Some founders convert notes early into a priced Series A round to eliminate the overhang before Series B diligence. Others negotiate with note holders to extend maturity or adjust caps in exchange for other economic terms. Neither path is simple, and both require legal counsel. The better outcome is structuring the original instruments with Series B economics in mind.

How does option pool expansion interact with convertible note conversion at Series B?

Both happen at the same time and both hit the pre-money. The option pool expansion is calculated before the new money lands, which means founders absorb that dilution alongside the convertible conversions. A 10% pool refresh plus 20% in convertible dilution can consume 30% of the company's pre-money value before the Series B investor's capital changes any ownership percentages.

What does a Series B investor actually do when they see a messy mixed convertible stack?

They model the fully diluted cap table at their target ownership percentage and work backward to a pre-money valuation that still makes the deal worth leading. If the convertible overhang is heavy, they either lower the pre-money (which hurts the founder), reduce their check size, require cleanup of some instruments as a closing condition, or pass. The cap table issues that kill a Series B before diligence are rarely about the instruments themselves. They are about what those instruments do to the economics of the round the lead is trying to lead.

Continue reading this series:

• That Seed Round Term Looked Fine. It's Now Costing You $8M at Series B
• You Raised Three SAFEs. Here's How They're About to Detonate at Your Series B
• The Convertible Note Overhang Problem: Why Uncapped Notes From Your Seed Round Are a Series B Red Flag

This isn't for pre-revenue companies or first-time founders. It's for operators at $1M+ ARR, raising $5M to $250M of institutional capital, who've done this before and want the next round architected right.If that's you, schedule a call to discuss HERE.